Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Clinical Data, Inc. (“Clinical Data” or the “Company”) (Nasdaq:CLDA) concerning the proposed acquisition of the Company by Forest Laboratories, Inc (“Forest”). Under the terms of the offer, Clinical Data shareholders will receive $30.00 in cash per share owned and contingent consideration of up to $6.00 per share based up upon the achievement of certain commercial milestones related to the Company’s antidepressant drug, Viibryd™. The transaction is valued at approximately $1.2 billion. The investigation is focused on the potential unfairness of the consideration to Clinical Data shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interests among Clinical Data Board members. In particular, according to Yahoo! Finance, at least one analyst has set a target price of $46.00 for Clinical Data shares. If you are interested in discussing your rights as a Clinical Data shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at email@example.com. Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Cheng Yi Liang, a chemist with the U.S. Food and Drug Administration, was charged by the Securities and Exchange Commission with insider trading on information regarding upcoming FDA drug approval decisions on Tuesday.